Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CWBR | CohBar, Inc.

Index	-	P/E	-	EPS (ttm)	-4.36	Insider Own	0.20%	Shs Outstand	2.91M	Perf Week	-3.34%
Market Cap	8.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.47M	Perf Month	2.12%
Income	-12.70M	PEG	-	EPS next Q	-	Inst Own	7.20%	Short Float / Ratio	1.27% / 1.19	Perf Quarter	-0.90%
Sales	-	P/S	-	EPS this Y	39.80%	Inst Trans	-8.74%	Short Interest	0.03M	Perf Half Y	84.08%
Book/sh	3.27	P/B	0.88	EPS next Y	-	ROA	-81.10%	Target Price	18.00	Perf Year	-31.78%
Cash/sh	4.24	P/C	0.68	EPS next 5Y	-	ROE	-88.90%	52W Range	1.43 - 6.90	Perf YTD	70.51%
Dividend	-	P/FCF	-	EPS past 5Y	11.80%	ROI	-	52W High	-58.12%	Beta	1.87
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	-	Gross Margin	-	52W Low	102.10%	ATR	0.21
Employees	9	Current Ratio	4.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	48.46	Volatility	5.18% 7.25%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-58.60%	Profit Margin	-	Rel Volume	0.20	Prev Close	2.91
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 14 AMC	Payout	-	Avg Volume	26.30K	Price	2.89
Recom	3.00	SMA20	-0.01%	SMA50	-2.80%	SMA200	24.45%	Volume	5,251	Change	-0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-21	Initiated	Aegis Capital	Buy	$6

Aug-14-23 04:01PM	CohBar Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-05-23 08:05AM	Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) (GlobeNewswire) -5.59%
May-30-23 08:05AM	Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-23 02:52PM	CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates (Benzinga) +223.23%
07:30AM	CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy (GlobeNewswire)
04:03PM	Loading…
Nov-08-22 04:03PM	CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Oct-26-22 09:00AM	CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022 (GlobeNewswire) +8.89%
Oct-21-22 12:00PM	Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-22-22 09:00AM	CohBar Announces Reverse Stock Split (GlobeNewswire)
Sep-06-22 09:00AM	CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-15-22 04:02PM	CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
Aug-01-22 09:00AM	CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022 (GlobeNewswire)
Jul-12-22 09:00AM	CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors (GlobeNewswire)
Jun-11-22 09:33AM	We're Keeping An Eye On CohBar's (NASDAQ:CWBR) Cash Burn Rate (Simply Wall St.)
Jun-07-22 09:00AM	CohBar to Participate at Upcoming Conferences in June 2022 (GlobeNewswire) -6.41%
04:02PM	Loading…
May-19-22 04:02PM	CohBar to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.74%
May-16-22 04:01PM	CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress (GlobeNewswire)
May-12-22 09:00AM	CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal (GlobeNewswire) +5.24%
May-02-22 09:00AM	CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022 (GlobeNewswire)
Mar-29-22 04:01PM	CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-15-22 09:00AM	CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022 (GlobeNewswire)
Jan-13-22 01:38PM	Tri-Star Advisors Inc. Buys iShares TIPS Bond ETF, iShares Fallen Angels USD Bond ETF, BTC ... (GuruFocus.com) -5.13%
Jan-03-22 09:00AM	CohBar to Present at H.C. Wainwright BIOCONNECT Conference (GlobeNewswire) +13.15%
Dec-31-21 11:22AM	7 of the Best Penny Stocks Under $3 for 2022 to Buy Now (InvestorPlace)
Dec-17-21 09:00AM	CohBar Announces Changes to its Board of Directors and R&D Leadership (GlobeNewswire)
Nov-29-21 09:00AM	CohBars CEO to Participate in Upcoming BIO Webinar (GlobeNewswire)
Nov-19-21 09:47AM	7 Penny Stocks With the Potential to 10X in 2022 (InvestorPlace)
Nov-15-21 04:02PM	CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) -5.32%
Nov-03-21 08:33AM	CohBar, Inc. (NASDAQ:CWBR) may have lost US$647k in value but insiders who invested last year have seen gains of around US$8.6k to date (Simply Wall St.)
Nov-02-21 01:14AM	Penny Stocks to Buy Using Technical Analysis for November 2021 (Investopedia)
09:00AM	Loading…
Nov-01-21 09:00AM	CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021 (GlobeNewswire) +8.00%
Oct-28-21 02:45PM	Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results (Benzinga) -37.83%
08:45AM	CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants (GlobeNewswire)
Oct-27-21 04:01PM	CohBar Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
Oct-13-21 09:00AM	CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021 (GlobeNewswire)
Sep-15-21 09:00AM	CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors (GlobeNewswire)
Sep-08-21 09:00AM	CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)
Sep-02-21 04:05PM	CohBar to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-21 09:46AM	5 Penny Stocks Insiders Are Buying (Benzinga) +9.35%
Aug-16-21 09:00AM	CohBar Appoints Carol Nast to Its Board of Directors (GlobeNewswire) -15.38%
Aug-12-21 12:50PM	10 Penny Stocks Redditors are Buying in August (Insider Monkey) -10.49%
Aug-10-21 04:04PM	CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
04:02PM	CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity (GlobeNewswire)
Aug-04-21 04:05PM	CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021 (GlobeNewswire)
Jul-14-21 09:00AM	CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity (GlobeNewswire) -18.12%
Jun-10-21 09:00AM	CohBar to Present at the BIO 2021 Digital Conference (GlobeNewswire)
May-17-21 04:02PM	CohBar Reports First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
03:15PM	CohBar, Inc. to Host Earnings Call (ACCESSWIRE)
May-03-21 09:00AM	CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021 (GlobeNewswire)
Apr-27-21 08:30AM	CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director (GlobeNewswire) -5.80%
Apr-22-21 09:56AM	New Strong Sell Stocks for April 22nd (Zacks) +6.90%
Apr-21-21 09:00AM	CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity (GlobeNewswire) +6.42%
Apr-14-21 09:00AM	CohBar to Present at the Mitochondria-Targeted Drug Development Summit (GlobeNewswire)
Mar-30-21 04:02PM	CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)
02:45PM	CohBar, Inc. to Host Earnings Call (ACCESSWIRE)
Mar-29-21 09:00AM	CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity (GlobeNewswire)
Mar-16-21 04:05PM	CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021 (GlobeNewswire)
09:00AM	CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases (GlobeNewswire)
Mar-12-21 09:00AM	CohBar to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference (GlobeNewswire)
Mar-02-21 09:00AM	CohBar to Present at the 33rd Annual ROTH Conference (GlobeNewswire)
Feb-25-21 09:00AM	CohBar to Present at the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) -7.14%
Feb-09-21 09:00AM	CohBar to Present at the BIO CEO & Investor Digital Conference (GlobeNewswire)
Jan-20-21 09:00AM	CohBar to Present at the 3rd Annual Longevity Therapeutics Conference (GlobeNewswire) +6.38%
Jan-11-21 09:00AM	CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS (GlobeNewswire)
Dec-09-20 09:00AM	CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model (GlobeNewswire)
Nov-19-20 09:00AM	CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference (GlobeNewswire)
Nov-16-20 04:01PM	CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
03:15PM	CohBar, Inc. to Host Earnings Call (ACCESSWIRE)
Nov-09-20 03:30PM	These 3 Penny Stocks Could Rally Over 100%, Says Roth Capital (TipRanks) +8.48%
Nov-02-20 09:00AM	CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020 (GlobeNewswire)
07:35AM	Forget Bargain Hunting: Play 5 Stocks With Rising P/E (Zacks)
Oct-29-20 09:00AM	CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Oct-27-20 09:00AM	CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event (GlobeNewswire)
Oct-26-20 09:00AM	CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model (GlobeNewswire)
Oct-15-20 04:05PM	CohBar to Present at the BIO-Europe Conference (GlobeNewswire)
Oct-08-20 09:00AM	CohBars CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference (GlobeNewswire)
Oct-05-20 09:00AM	CohBar to Present at the BIO Investor Forum (GlobeNewswire)
Sep-29-20 04:05PM	CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference (GlobeNewswire)
Sep-10-20 04:05PM	CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit (GlobeNewswire)
Sep-04-20 11:24AM	Insider Buys CohBar's Stock (Benzinga) +6.00%
Sep-03-20 08:45AM	CohBar to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire) -10.71%
Aug-28-20 04:05PM	CohBar Announces Closing of Public Offering of Common Stock and Warrants (GlobeNewswire) +8.00%
Aug-26-20 08:30AM	CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants (GlobeNewswire) -32.64%
Aug-25-20 04:55PM	CohBar Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
Aug-24-20 09:00AM	CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity (GlobeNewswire)
Aug-13-20 04:03PM	CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-20 09:00AM	CohBar Presents New Antifibrotic Data at the American Thoracic Societys Virtual 2020 Conference (GlobeNewswire) +8.39%
Jul-30-20 09:00AM	CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 (GlobeNewswire)
Jul-07-20 09:00AM	CohBar Resumes CB4211 Phase 1b Clinical Trial (GlobeNewswire)
Jul-06-20 09:00AM	CohBar to Present at Sachs Novel Coronavirus Investment Forum (GlobeNewswire) +6.00%
Jun-30-20 09:00AM	CohBar Added to Russell 2000® Index and Raises $4.4M in ATM Offering (GlobeNewswire)
Jun-17-20 09:00AM	CohBar Founder Dr. Nir Barzilais New Book AGE LATER Reveals that Aging Can Be Seen as a Preventable Disease (GlobeNewswire)
Jun-02-20 09:00AM	CohBar to Hold 2020 Annual Shareholder Meeting and Investor Update June 16, 2020 (GlobeNewswire) +6.43%
May-27-20 09:00AM	CohBars CEO to Participate on the New Breakthroughs in Aging Biology Panel at the BIO 2020 Digital Conference (GlobeNewswire)
May-14-20 04:02PM	CohBar Reports First Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) -12.50%
May-13-20 09:00AM	CohBars Chief Operating Officer Jon Stern Plans to Step Down from Management Role (GlobeNewswire) -8.72%
May-05-20 09:00AM	CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides (GlobeNewswire) +19.40%
May-01-20 11:00AM	CohBars Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine (GlobeNewswire) +10.98%
Apr-30-20 09:00AM	CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020 (GlobeNewswire) -6.25%
Apr-19-20 09:21AM	Is CohBar, Inc. (NASDAQ:CWBR) A Volatile Stock? (Simply Wall St.)

CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CWBR | CohBar, Inc.

Upgrade your FINVIZ experience